|By Marketwired .||
|January 14, 2013 08:00 AM EST||
BOCA RATON, FL -- (Marketwire) -- 01/14/13 -- Atossa Genetics (NASDAQ: ATOS), the Breast Health Company, based in Seattle, Washington, and Clarity Women's Health (a division of Diagnostic Test Group, LLC) of Boca Raton, Florida, announced today the launch of the ForeCYTE Breast Health Test at Clarity's national sales meeting, held on January 10-11th, 2013, in Boca Raton, Florida. The patented ForeCYTE Breast Health Test is designed for the early detection of precancerous breast conditions and the determination of the future risk of breast cancer, using a clinically validated algorithm including family history, personal reproductive history and breast cytopathology. The ForeCYTE Test, which uses the patented, FDA-cleared MASCT Breast Health System to painlessly collect a tiny sample of nipple ductal fluid, is designed to be performed at the point of care in a non-invasive and highly sensitive manner.
"Clarity Women's Health brings tremendous relationships with its clients driven by highly skilled technical support and customer service teams. I believe we have a strong national launch strategy working with the Clarity team and we anticipate rapid adoption as physicians' access to the ForeCYTE test is expanded," said Chris Destro, Vice President of Sales and Marketing, Atossa Genetics, Inc. "The passion and commitment of the entire team at Clarity Women's Health to make a difference in the current paradigm of breast health is palpable."
"The ForeCYTE Breast Health Test is the cornerstone of our new division, Clarity Women's Health," stated Daniel Léger, Vice President of Sales and Marketing, Diagnostic Test Group, LLC. "This product is targeted for over 110 million women between the ages of 18 and 73 in the U.S. who can now obtain a simple test in their physician's office and learn their future risk of breast cancer up to eight years before mammography can pick it up. This kind of advanced information was created for cervical cancer by the Pap smear and was responsible for the 75% reduction in the incidence of cervical cancer. The ForeCYTE Breast Health Test has the potential to do the same for breast cancer."
For more information, please click the following link to view a video interview with Christopher Destro, VP of Sales and Marketing of Atossa genetics discussing aspects of this press release in more detail: http://client.irwebkit.com/AtossaGenetics/media. You may also sign up to receive automatic email News Alert updates there.
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
About Clarity Women's Health
Clarity Women's Health is a division of Diagnostic Test Group, LLC in Boca Raton, FL, and is a sales, marketing and branding company focused on the sale and distribution of its own Clarity brand of rapid and diagnostic tests, molecular tests, and diagnostic equipment utilized in physicians' offices, clinics, labs, urgent care centers and hospitals. DTG offers one of the largest lines of diagnostic tests in the industry supported by its own national sales force combined with in-house 24 hour customer service and tech support. Clarity products are available at most of the recognized national distributors. The ForeCYTE Breast Health System will form the cornerstone of its newly created division, Clarity Women's Health.
Video-Link Available: http://www2.marketwire.com/mw/frame_mw?attachid=2200451